Salesforce Friends ...
Health Care: Drugs
Dendreon Corp (DNDN: NASDAQ)
$5.91 -0.85 | -12.57%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 3.93 | 0.58 | 0.98 |
| Price to Sales (TTM) | 2.62 | 4.62 | 1.42 |
| Price to Book (MRQ) | 3.72 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 3.72 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -4.00 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 192.50 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 610.80 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 319.92 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 63.30 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 6.20 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 7.30 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 2.04 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 2.05 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 66.50 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 76.80 | 83.50 | 47.70 |
| EBITD Margin (TTM) | -42.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -231.71 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -82.30 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.82 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -34.80 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -44.10 | 2.20 | 2.50 |
| Return on Investment (TTM) | -38.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -51.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 269,872.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -222,045.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 13.60 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 2.40 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.40 | 0.40 | 0.40 |
Portfolios with DNDN
- Portfolio NameUser Type
- UserLong Term Stock Picks
- UserTop 10 Small Cap Stock Picks
- ContributorBreakout Stocks Of The Week...
- UserS ACCT
- UserRISK
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorRelative Strength Trades fo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
Latest DNDN Headlines from TheStreet
- Dendreon Stock Hits New 52-Week Low (DNDN) 06.04.12 | 10:06 am
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- J&J Scores Big With Prostate Cancer Pill 06.02.12 | 12:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - Dendreon Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript) 05.17.12 | 01:05 am
- Dendreon Management Presents At Deutsche Bank Securities, Inc. 37th Annual Health Care Conference (Transcript) 05.11.12 | 07:05 pm
- Dendreon Stock Gaps Down On Today's Open (DNDN) 05.08.12 | 08:05 am
Press Releases for DNDN
- Dendreon Announces Webcast Presentations At Upcoming Conferences - Business Wire 05.25.12 | 08:05 pm
- Dendreon Announces Data Presentation At The 2012 American Urological Association Annual Meeting - Business Wire 05.21.12 | 10:05 am
- Dendreon Announces Presentation Of PROVENGE Data At The 2012 American Society Of Clinical Oncology Annual Meeting - Business Wire 05.16.12 | 06:05 pm
- Dendreon Reports Net PROVENGE Product Revenues Of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth - Business Wire 05.07.12 | 04:05 pm
- Jennerex Elects Dr. Mitchell H. Gold To Board Of Directors - PR Newswire 04.17.12 | 07:04 am
- Dendreon To Host Conference Call On May 7 To Announce First Quarter Financial Results And Webcast Presentations At Upcoming Conferences - Business Wire 04.09.12 | 05:04 pm
- Genesis Biopharma Names Biotech Industry Veteran Hans E. Bishop As Executive Chairman Of The Board - PR Newswire 03.22.12 | 08:03 am
- Dendreon Announces Webcast Presentation At Upcoming Conferences - Business Wire 03.05.12 | 08:03 am
- Dendreon Announces Executive Appointments - Business Wire 02.28.12 | 05:02 pm
- Dendreon Reports Fourth Quarter And 2011 Year End Financial Results - Business Wire 02.27.12 | 08:02 am
Partner Headlines for DNDN
- Analyst Alerts: General Motors, Valero, Copa Holdings, Dendreon June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Active Stock Alerts: Dendreon, Delcath Systems, Johnson & Johnson, Boeing, Onyx June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Stock Insights: Dendreon, Medtronic, FedEx, ArQule, Rentrak June 4th - Wall St. Cheat Sheet 06.04.12 | 10:06 am
- Social Media Outlook for Monday June 4 (AUXL, NFLX, DNDN, IBM) - Benzinga 06.04.12 | 09:06 am
- Healthcare Business Recap: Dendreon BOMBS, Cancer Cures Galore - Wall St. Cheat Sheet 06.04.12 | 06:06 am
- J&J and 2 Dow 30 Stocks BUZZING Now - Wall St. Cheat Sheet 06.04.12 | 04:06 am
- 3 BOMBS Getting Dropped on Dendreon Now - Wall St. Cheat Sheet 06.04.12 | 03:06 am
- Baxter And Neostem Validating Each Other's Cell Therapies - Seeking Alpha 06.01.12 | 09:06 am
- IsoRay: A Potential Small-Cap Bio-Pharma Multi-Bagger - Seeking Alpha 05.29.12 | 09:05 am
- Analyst Alerts: VeriFone, Dendreon, TD Bank May 25th - Wall St. Cheat Sheet 05.25.12 | 11:05 am
